Research shows treating HIV-AIDS with interleukin-2 is ineffective
A team of researchers at the MUHC/鶹AV and their
international colleagues recommend halting all clinical trials on
interleukin-2.
An international research team has demonstrated that treating
HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the
researchers recommend that clinical trials on this compound be
stopped. Their finding was published in the New England Journal
of Medicine in an article co-authored by 14 researchers,
including Dr. Jean-Pierre Routy of the Research Institute of the
鶹AV Health Centre (RI-MUHC).
IL-2 is currently used as a complement to highly active
antiretroviral therapy (known as HAART), which is administered to
patients with HIV-AIDS. Since HAART controls replication of viruses
in the blood, doctors thought that IL-2 would help regenerate more
CD4+ immune cells, which serve as an indicator of viral
progression. It was thought that IL-2 increased the natural
immunity of patients by helping immune cells mature and
multiply.
“Our results show that IL-2 has no effect on the development of
AIDS or on patient survival,” says Dr. Routy. “More precisely,
while the presence of IL-2 leads to a faster increase of CD4+
immune cells, these cells are less functional than the CD4+ cells
that regenerate naturally in patients who do not receive IL-2. This
means that IL-2 treatment provides no benefit and does not prevent
AIDS-related infectious diseases.”
“For the first time, a study has shed light on recurring questions
concerning the value of biological markers and their limitations in
assessing patient health,” explains Dr. Routy. “Our challenge now
will be to develop tests that assess the function of immune cells
and not simply their quantity. This will ensure that HIV treatments
indeed have a clinical benefit for patients.”
This 8-year study involved over 5000 patients in 25 countries, and
was one of the largest ever conducted on HIV-AIDS. “The fact that
data from developing countries was used in biomedical research on
innovative compounds is very revolutionary in the history of
HIV-AIDS research,” explains Dr. Routy.
is a physician in the
Division of Hematology and Immunodeficiency at the MUHC as well as
a researcher in the Infection and Immunity Axis at the Research
Institute of the MUHC. He is also an Associate Professor of
Hematology at 鶹AV and a senior clinical researcher
with the Fonds de la recherche en santé du Québec (FRSQ).
Funding
This study was funded by a grant from the National Institutes of
Health (NIH)
Partners
This article was co-authored by Dr. D. Abrams, University of
California, San Francisco; Dr. Y. Lévy, INSERM U955, Université
Paris 12, et Assistance Publique-Hôpitaux de Paris, Groupe
Henri-Mondor Albert-Chenevier, Dr. M.H. Losso, Hospital General de
Agudos, Dr. J.M. Ramos Mejia, Buenos Aires; Dr. A. Babiker, Medical
Research Council, London; Dr. G. Collins, University of Minnesota,
Minneapolis; Dr. D. Cooper, National Centre in HIV Epidemiology and
Clinical Research, Sydney; Dr. J. Darbyshire, Medical Research
Council, London; Dr. S. Emery, National Centre in HIV Epidemiology
and Clinical Research, Sydney; Dr. L. Fox, National Institute of
Allergy and Infectious Diseases, Bethesda; Dr. F. Gordin,
Washington Veterans Medical Center, Washington, DC; Dr. H.C. Lane,
National Institutes of Health, Bethesda; Dr. J.D. Lundgren,
Rigshospitalet & University of Copenhagen, Copenhagen; Dr. R.
Mitsuyasu, University of California, Los Angeles; Dr. J.D. Neaton,
University of Minnesota, Minneapolis; Dr. A. Phillips, University
College London Medical School, London; Dr. J.P Routy, Royal
Victoria Hospital, 鶹AV Health Centre; Dr. G.
Tambussi, Fondazione San Raffaele del Monte Tabor, Milano; Dr. D.
Wentworth, University of Minnesota, Minneapolis.
The Research Institute of the 鶹AV Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, the university health center affiliated with the Faculty of Medicine at 鶹AV University. The institute supports over 600 researchers, nearly 1200 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge.
The Research Institute of the MUHC is supported in part by the Fonds de la recherche en santé du Québec. For further details visit:
You will find this press release, with the original article and a short audio interview by following this link:
For more information please contact:
Julie Robert
Communications Coordinator (research)
MUHC Public Affairs & Strategic Planning
(514) 843 1560
julie.robert [at] muhc.mcgill.ca